Clinical characteristics of ATLL patients who achieved first CR by regimen
| Patient code . | ATLL subtype . | LDH × UNL . | Calcium level, mg/dL . | Extranodal involvement . | WBC/ALC × 109/L . | Regimen used prior to CR . | Outcome/status . | PFS . |
|---|---|---|---|---|---|---|---|---|
| ATLL-1 | Acute | 6.3 | 13.6 | PB/liver | 13/10 | AI as second line (failed CHOP-like/fludarabine) | Relapsed (as lymphomatous)/deceased | 6.3 y |
| ATLL-2 | Acute | 4.8 | 9.1 | PB/liver | 37/31 | AI | Relapsed (as lymphomatous)/deceased | 6.3 y |
| ATLL-3 | Unf chronic | 1.1 | 9.1 | PB | 28/23 | AI | Relapsed/alive | 10.6 y |
| ATLL-4 | Acute* | 6.2 | 8.7 | BM/PB/skin | 36.6/9.7 | AI | Sustained response/alive | 3.3 y |
| ATLL-14 | Acute | 2.3 | 9.9 | BM/PB | 152/115 | CHOP after AI | Lost follow up | 2 mo |
| ATLL-21 | Unf chronic | 2.4 | 9.6 | PB | 61/52 | AI | Relapsed (as lymphomatous) | 3.4 y |
| ATLL-22 | Acute | 7.7 | 12.5 | PB | 153/141 | Etoposide (oral) | Relapsed/deceased | 4 mo |
| ATLL-23 | Acute | 1 | 9.3 | PB/GI | 1.5/1.3 | EPOCH + AI maintenance | Relapsed/deceased | 6 mo |
| ATLL-24 | Acute | 6.8 | 12.2 | Skin/lung/PB | 102/84.7 | Etoposide (oral) | Relapsed/deceased | 5 mo |
| ATLL-26 | Acute† | 4.3 | 9.2 | PB | 53/47 | Etoposide (oral) | Relapsed/deceased | 14 mo |
| ATLL-27 | Acute | 2.4 | 10.4 | PB/skin | 89/84 | AI | Relapsed/deceased | 2.6 y |
| ATLL-29 | Lymphomatous | 1 | 9.7 | BM/nasopharynx | 4.6/1.8 | EPOCH + AI maintenance | Relapsed/deceased | 13 mo |
| ATLL-33 | Lymphomatous | 5.9 | 10.5 | Parotid, CNS | 7.9/2.7 | Brain XRT followed by high-dose MTX/AZT | Relapsed/deceased | 7 mo |
| ATLL-54 | Acute | 2.9 | 13.9 | Lung/pleura/pericardium | 55/28 | AI | Relapsed/deceased | 3.2 y |
| ATLL-55 | Acute | 5 | 14.9 | PB/lung/pleura/skin | 64/59 | CHOP as second-line (after AI) | Relapsed/deceased | 3 mo |
| ATLL-59 | Lymphomatous | 5.2 | 2.5 | None | 5.2/2.5 | CHOP | Relapsed/deceased | 17 mo |
| ATLL-60 | Acute | 4.6 | 10.3 | PB/skin/liver | 23/16 | AI | Lost follow-up/deceased | 9.2 mo |
| ATLL-66 | Lymphomatous | 3.2 | 9.3 | Skin | 4.0/1.0 | AI | Relapsed/deceased | 2.4 mo |
| ATLL-84 | Acute | 3 | 12.1 | PB/skin | 250 (PP)→40/26 | AI | Relapsed/deceased | 3.8 y |
| ATLL-87 | Lymphomatous | 1.3 | 12.1 | Skin | 14/2.9 | EPOCH | Relapsed/deceased | 16 mo |
| ATLL-93 | Lymphomatous | 1.5 | 9.4 | None | 3.9/2.1 | VCAP-AP-VECP | Lost to follow-up/deceased | 18 mo |
| ATLL-100 | Lymphomatous | 1 | 9.7 | Bone | 4.9/1.2 | EPOCH | Relapsed/deceased | 14 mo |
| ATLL-101 | Acute | 1.2 | 17.8 | Skin/lung/PB/BM | 50/14 | CHOP | Relapsed/deceased | 28 mo |
| ATLL-103 | Acute | 2.5 | 16.5 | Skin/bone/BM/PB | 52/38 | VCAP-AP-VECP as second-line (after AI) | Relapsed/deceased | 16 mo |
| ATLL-104 | Acute | 2.8 | 10.1 | Skin/PB | 32/23 | AI | Relapsed/deceased | 7 mo |
| ATLL-106 | Acute | Unk | 19.6 | BM/PB | 37/Unk | VCAP-AP-VECP | Relapsed/deceased | 3 mo |
| ATLL-107 | Acute | 2.1 | 9.7 | Skin/lung/bone/pharynx | 20/14 | AI | Relapsed/deceased | 4 mo |
| ATLL-108 | Acute | Unk | 14 | Bone/PB | “Elevated” | VCAP-AP-VECP | Relapsed/deceased | 10 mo |
| ATLL-110 | Acute | 1.8 | 11.1 | PB/BM | 62/53 | AI as 3rd (failed EPOCH 1 cycle, and ICE 1 cycle) | Sustained response/alive | 6 y |
| ATLL-114 | Lymphomatous | 1.4 | 13 | CNS | 7/1.2 | High-dose MTX/AZT | Relapsed/deceased | 7 mo |
| ATLL-115 | Lymphomatous | 1 | 10.2 | None | 4/1.7 | EPOCH/bortezomib/ raltegravir | Relapsed/deceased | 2.3 y |
| ATLL-119 | Lymphomatous | Unk | Unk | GI/pleura/BM | Unk/Unk | VCAP-AP-VECP followed by allo-HCT | Death from infection during transplant | 9 mo |
| ATLL-120 | Lymphomatous | Unk | 9 | None | 6.2/2.1 | EPOCH + AZT maintenance | Relapsed/deceased | 13 mo |
| ATLL-123 | Lymphomatous | 14 | Unk | Liver/BM | Unk/Unk | CHOP/CODOX/ICE | Relapsed/lost to follow-up | 8 mo |
| ATLL-126 | Acute | 4.5 | 9.6 | GI/PB | 31/15 | VCAP-AP-VECP | Relapsed/deceased | 7 mo |
| ATLL-136 | Acute | 12.7 | 12 | Bone/PB | 57/36 | ProMACE-CytaBOM | Lost to follow-up/unknown | 14 mo |
| ATLL-137 | Acute | Unk | Unk | Liver/BM/PB | 27/13 | ProMACE-CytaBOM | Relapsed/deceased | 18 mo |
| ATLL-179 | Lymphomatous | 3.8 | 8 | GI | 11.7/2 | VCAP-AP-VECP followed by allo-HCT | Relapsed/deceased | 13 mo |
| ATLL-180 | Lymphomatous | 1.4 | 11 | BM | Unk/1.4 | CHOP | Relapsed/deceased | 6 mo |
| ATLL-181 | Lymphomatous | 1.3 | 11.2 | None | 6.2/2.9 | CHOEP | Relapsed/alive | 14 mo‡ |
| ATLL-193 | Acute | 5.8 | 14 | PB/kidney | 89/49 | AI | Relapsed/deceased | 1 mo |
| ATLL-194 | Lymphomatous | Unk | Unk | BM/GI | Unk/Unk | CHOP | Relapsed/deceased | 8 mo |
| ATLL-197 | Acute | 8 | 16 | Bone/PB/BM | 272/245 | CHOP | Relapsed/deceased | 6 mo |
| ATLL-200 | Acute | 3.4 | 12.3 | Liver/PB/BM | 45/21 | VCAP-AP-VECP as second-line (after AI) | Death from sepsis | 3 mo |
| ATLL-208 | Lymphomatous | 1.9 | 8.1 | None | 5.9/2.9 | CHOP | Sustained response/alive | 21 mo |
| ATLL-212 | Lymphomatous | 1 | 7.8 | None | 2.5/1.4 | CHOP | Relapsed/deceased | 16 mo |
| ATLL-214 | Lymphomatous | 1.1 | 7.1 | GI/liver/lung | 4.4/1.2 | CHOP | Relapsed/deceased | 7 mo |
| ATLL-215 | Acute | 9 | 8.7 | BM/PB | 28/12.3 | CHOEP followed by allo-HCT | Relapsed/deceased after failure to engraft | 11 mo‡ |
| ATLL-216 | Acute | 3.4 | 14 | Bone/skin/PB | 161/146 | AI | Sustained response/alive | 10 mo |
| ATLL-218 | Lymphomatous | Unk | Unk | None | 4.6/Unk | CHOP | Relapsed/deceased | 8 mo |
| ATLL-224 | Lymphomatous | Unk | Unk | BM/bone/skin | 7.1/1.5 | EPOCH | Relapsed/alive | 6 mo |
| Patient code . | ATLL subtype . | LDH × UNL . | Calcium level, mg/dL . | Extranodal involvement . | WBC/ALC × 109/L . | Regimen used prior to CR . | Outcome/status . | PFS . |
|---|---|---|---|---|---|---|---|---|
| ATLL-1 | Acute | 6.3 | 13.6 | PB/liver | 13/10 | AI as second line (failed CHOP-like/fludarabine) | Relapsed (as lymphomatous)/deceased | 6.3 y |
| ATLL-2 | Acute | 4.8 | 9.1 | PB/liver | 37/31 | AI | Relapsed (as lymphomatous)/deceased | 6.3 y |
| ATLL-3 | Unf chronic | 1.1 | 9.1 | PB | 28/23 | AI | Relapsed/alive | 10.6 y |
| ATLL-4 | Acute* | 6.2 | 8.7 | BM/PB/skin | 36.6/9.7 | AI | Sustained response/alive | 3.3 y |
| ATLL-14 | Acute | 2.3 | 9.9 | BM/PB | 152/115 | CHOP after AI | Lost follow up | 2 mo |
| ATLL-21 | Unf chronic | 2.4 | 9.6 | PB | 61/52 | AI | Relapsed (as lymphomatous) | 3.4 y |
| ATLL-22 | Acute | 7.7 | 12.5 | PB | 153/141 | Etoposide (oral) | Relapsed/deceased | 4 mo |
| ATLL-23 | Acute | 1 | 9.3 | PB/GI | 1.5/1.3 | EPOCH + AI maintenance | Relapsed/deceased | 6 mo |
| ATLL-24 | Acute | 6.8 | 12.2 | Skin/lung/PB | 102/84.7 | Etoposide (oral) | Relapsed/deceased | 5 mo |
| ATLL-26 | Acute† | 4.3 | 9.2 | PB | 53/47 | Etoposide (oral) | Relapsed/deceased | 14 mo |
| ATLL-27 | Acute | 2.4 | 10.4 | PB/skin | 89/84 | AI | Relapsed/deceased | 2.6 y |
| ATLL-29 | Lymphomatous | 1 | 9.7 | BM/nasopharynx | 4.6/1.8 | EPOCH + AI maintenance | Relapsed/deceased | 13 mo |
| ATLL-33 | Lymphomatous | 5.9 | 10.5 | Parotid, CNS | 7.9/2.7 | Brain XRT followed by high-dose MTX/AZT | Relapsed/deceased | 7 mo |
| ATLL-54 | Acute | 2.9 | 13.9 | Lung/pleura/pericardium | 55/28 | AI | Relapsed/deceased | 3.2 y |
| ATLL-55 | Acute | 5 | 14.9 | PB/lung/pleura/skin | 64/59 | CHOP as second-line (after AI) | Relapsed/deceased | 3 mo |
| ATLL-59 | Lymphomatous | 5.2 | 2.5 | None | 5.2/2.5 | CHOP | Relapsed/deceased | 17 mo |
| ATLL-60 | Acute | 4.6 | 10.3 | PB/skin/liver | 23/16 | AI | Lost follow-up/deceased | 9.2 mo |
| ATLL-66 | Lymphomatous | 3.2 | 9.3 | Skin | 4.0/1.0 | AI | Relapsed/deceased | 2.4 mo |
| ATLL-84 | Acute | 3 | 12.1 | PB/skin | 250 (PP)→40/26 | AI | Relapsed/deceased | 3.8 y |
| ATLL-87 | Lymphomatous | 1.3 | 12.1 | Skin | 14/2.9 | EPOCH | Relapsed/deceased | 16 mo |
| ATLL-93 | Lymphomatous | 1.5 | 9.4 | None | 3.9/2.1 | VCAP-AP-VECP | Lost to follow-up/deceased | 18 mo |
| ATLL-100 | Lymphomatous | 1 | 9.7 | Bone | 4.9/1.2 | EPOCH | Relapsed/deceased | 14 mo |
| ATLL-101 | Acute | 1.2 | 17.8 | Skin/lung/PB/BM | 50/14 | CHOP | Relapsed/deceased | 28 mo |
| ATLL-103 | Acute | 2.5 | 16.5 | Skin/bone/BM/PB | 52/38 | VCAP-AP-VECP as second-line (after AI) | Relapsed/deceased | 16 mo |
| ATLL-104 | Acute | 2.8 | 10.1 | Skin/PB | 32/23 | AI | Relapsed/deceased | 7 mo |
| ATLL-106 | Acute | Unk | 19.6 | BM/PB | 37/Unk | VCAP-AP-VECP | Relapsed/deceased | 3 mo |
| ATLL-107 | Acute | 2.1 | 9.7 | Skin/lung/bone/pharynx | 20/14 | AI | Relapsed/deceased | 4 mo |
| ATLL-108 | Acute | Unk | 14 | Bone/PB | “Elevated” | VCAP-AP-VECP | Relapsed/deceased | 10 mo |
| ATLL-110 | Acute | 1.8 | 11.1 | PB/BM | 62/53 | AI as 3rd (failed EPOCH 1 cycle, and ICE 1 cycle) | Sustained response/alive | 6 y |
| ATLL-114 | Lymphomatous | 1.4 | 13 | CNS | 7/1.2 | High-dose MTX/AZT | Relapsed/deceased | 7 mo |
| ATLL-115 | Lymphomatous | 1 | 10.2 | None | 4/1.7 | EPOCH/bortezomib/ raltegravir | Relapsed/deceased | 2.3 y |
| ATLL-119 | Lymphomatous | Unk | Unk | GI/pleura/BM | Unk/Unk | VCAP-AP-VECP followed by allo-HCT | Death from infection during transplant | 9 mo |
| ATLL-120 | Lymphomatous | Unk | 9 | None | 6.2/2.1 | EPOCH + AZT maintenance | Relapsed/deceased | 13 mo |
| ATLL-123 | Lymphomatous | 14 | Unk | Liver/BM | Unk/Unk | CHOP/CODOX/ICE | Relapsed/lost to follow-up | 8 mo |
| ATLL-126 | Acute | 4.5 | 9.6 | GI/PB | 31/15 | VCAP-AP-VECP | Relapsed/deceased | 7 mo |
| ATLL-136 | Acute | 12.7 | 12 | Bone/PB | 57/36 | ProMACE-CytaBOM | Lost to follow-up/unknown | 14 mo |
| ATLL-137 | Acute | Unk | Unk | Liver/BM/PB | 27/13 | ProMACE-CytaBOM | Relapsed/deceased | 18 mo |
| ATLL-179 | Lymphomatous | 3.8 | 8 | GI | 11.7/2 | VCAP-AP-VECP followed by allo-HCT | Relapsed/deceased | 13 mo |
| ATLL-180 | Lymphomatous | 1.4 | 11 | BM | Unk/1.4 | CHOP | Relapsed/deceased | 6 mo |
| ATLL-181 | Lymphomatous | 1.3 | 11.2 | None | 6.2/2.9 | CHOEP | Relapsed/alive | 14 mo‡ |
| ATLL-193 | Acute | 5.8 | 14 | PB/kidney | 89/49 | AI | Relapsed/deceased | 1 mo |
| ATLL-194 | Lymphomatous | Unk | Unk | BM/GI | Unk/Unk | CHOP | Relapsed/deceased | 8 mo |
| ATLL-197 | Acute | 8 | 16 | Bone/PB/BM | 272/245 | CHOP | Relapsed/deceased | 6 mo |
| ATLL-200 | Acute | 3.4 | 12.3 | Liver/PB/BM | 45/21 | VCAP-AP-VECP as second-line (after AI) | Death from sepsis | 3 mo |
| ATLL-208 | Lymphomatous | 1.9 | 8.1 | None | 5.9/2.9 | CHOP | Sustained response/alive | 21 mo |
| ATLL-212 | Lymphomatous | 1 | 7.8 | None | 2.5/1.4 | CHOP | Relapsed/deceased | 16 mo |
| ATLL-214 | Lymphomatous | 1.1 | 7.1 | GI/liver/lung | 4.4/1.2 | CHOP | Relapsed/deceased | 7 mo |
| ATLL-215 | Acute | 9 | 8.7 | BM/PB | 28/12.3 | CHOEP followed by allo-HCT | Relapsed/deceased after failure to engraft | 11 mo‡ |
| ATLL-216 | Acute | 3.4 | 14 | Bone/skin/PB | 161/146 | AI | Sustained response/alive | 10 mo |
| ATLL-218 | Lymphomatous | Unk | Unk | None | 4.6/Unk | CHOP | Relapsed/deceased | 8 mo |
| ATLL-224 | Lymphomatous | Unk | Unk | BM/bone/skin | 7.1/1.5 | EPOCH | Relapsed/alive | 6 mo |
AI, zidovudine and interferon-α; ALC, absolute lymphocyte count; BM, bone marrow; Ca, calcium; GI, gastrointestinal tract; LN, lymph node; MTX, methotrexate; PB, peripheral blood; PP, plasma exchange; Unf chronic, unfavorable chronic; UNL, upper normal limit; Unk, unknown; WBC, white blood cell count.
Patient transformed from unfavorable chronic to acute ATLL prior to AZT-INF.
Patient transformed from smoldering to acute ATLL prior to etoposide.
Censored prior to the transplant conditioning regimen.